Kairos Pharma (KAPA) Stock Price, News & Analysis

Company Overview

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics. The company collaborates with academic institutions and patient advocacy groups to advance its programs through clinical milestones and facilitate patient access. By concentrating on precision modulation of the translational machinery, Kairos Pharma aims to address diseases with high unmet medical need and no currently approved treatments.

Governed by an experienced leadership team with backgrounds in drug development, regulatory affairs and commercial strategy, Kairos Pharma maintains research operations in the United States and Europe. The company continues to forge strategic partnerships and secure financing to support its development programs and expand its pipeline. With a science‐driven approach and commitment to rare disease communities, Kairos Pharma is positioned to deliver innovative therapies to patients worldwide.

Key Stats

• Today's Range: $0.56 to $0.57
• 50-Day Range: $0.55 to $0.68
• 52-Week Range: $0.40 to $2.11
• Volume: 40,638 shs
• Average Volume: 407,832 shs
• Market Capitalization: $12.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Kairos Pharma Stock Analysis - MarketRank™

Kairos Pharma scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kairos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Kairos Pharma has a consensus price target of $9.00, representing about 1,504.3% upside from its current price of $0.56.

Amount of Analyst Coverage

Kairos Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kairos Pharma are expected to decrease in the coming year, from ($0.38) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kairos Pharma is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kairos Pharma is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kairos Pharma has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of Kairos Pharma has been sold short.

Short Interest Ratio / Days to Cover

Kairos Pharma has a short interest ratio ("days to cover") of 2.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kairos Pharma has recently decreased by 37.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kairos Pharma does not currently pay a dividend.

Dividend Growth

Kairos Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Kairos Pharma this week, compared to 1 article on an average week.

Search Interest

3 people have searched for KAPA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kairos Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.30% of the stock of Kairos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Kairos Pharma has minimal institutional ownership at this time.

KAPA Stock Analysis - Frequently Asked Questions

How have KAPA shares performed this year?

Kairos Pharma's stock was trading at $0.71 at the start of the year. Since then, KAPA stock has decreased by 21.0% and is now trading at $0.5610.

How were Kairos Pharma's earnings last quarter?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) issued its quarterly earnings results on Tuesday, March, 31st. The company reported ($0.07) earnings per share (EPS) for the quarter.

How do I buy shares of Kairos Pharma?

Shares of KAPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:KAPA
• CIK: 1962011
• Web: N/A
• Phone: (818) 404-5541
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kairos Pharma: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +1,504.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -80.30%
• Return on Assets: -74.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.07
• Quick Ratio: 27.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 1.87

Miscellaneous

• Outstanding Shares: 21,410,000
• Free Float: 14,281,000
• Market Cap: $12.01 million
• Optionable: N/A
• Beta: 1.51